Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 4 of 128 for:    "Pancreatic Neuroendocrine Tumor"

Lanreotide 120mg Effectiveness in Subjects With Pancreatic Neuroendocrine Tumours (PanNET) in Routine Clinical Practice. (PanNET)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03947762
Recruitment Status : Recruiting
First Posted : May 13, 2019
Last Update Posted : July 25, 2019
Sponsor:
Information provided by (Responsible Party):
Ipsen

Brief Summary:
The purpose of the protocol is to estimate the progression-free survival (PFS) rate in subjects diagnosed with PanNET, according to investigator assessment, at 24 months after treatment initiation with lanreotide 120 mg every 28 days.

Condition or disease
Pancreatic Neuroendocrine Tumor

Layout table for study information
Study Type : Observational
Estimated Enrollment : 196 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Lanreotide 120 mg Effectiveness in Subjects With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumours (PanNET) in Routine Clinical Practice
Actual Study Start Date : July 3, 2019
Estimated Primary Completion Date : January 31, 2023
Estimated Study Completion Date : January 31, 2023





Primary Outcome Measures :
  1. Progression-free survival (PFS) rate at 24 months [ Time Frame: 24 months ]
    To estimate the progression-free survival (PFS) rate in subjects diagnosed with PanNET, according to investigator assessment.


Secondary Outcome Measures :
  1. Progression-free survival (PFS) rate at 12 months [ Time Frame: 12 months ]
    PFS rate at 12 months after lanreotide treatment initiation according to investigator assessment

  2. Medical tumour-related intervention [ Time Frame: Baseline ]
    Description of the disease history management of subjects with PanNET will be collected by the investigator and recorded in an eCRF designed for the study

  3. Time from diagnosis to first therapeutic intervention [ Time Frame: Baseline ]
    Description of the disease history management of subjects with PanNET

  4. Quality of Life (QoL) [ Time Frame: From baseline up to 24 months ]
    To describe the change in Quality of Life (QoL) as assessed by European Organisation for Research and Treatment of Cancer (EORTC) QoL questionnaire for gastrointestinal neuroendocrine tumours (QLQ-GINET21) questionnaires.Where the patient assess experienced symptoms or problems using the scale from 1 to 4. Where 1 represents "not at all" and 4 "very much".

  5. Median time to lanreotide discontinuation [ Time Frame: Up to 24 months ]
  6. Changes of Chromogranin A (CgA) levels [ Time Frame: Every 6 months up to 24 months ]
    Changes in CgA levels between last CgA value prior to lanreotide start (if available) and values at each study visit

  7. Changes of Glycated hemoglobin (HbA1c) levels [ Time Frame: Every 6 months up to 24 months ]
    Changes in HbA1c levels between last HbA1c value prior to lanreotide start (if available) and values at each study visit

  8. Changes of urine 5-Hydroxyindoleacetic Acid (5-HIAA) levels [ Time Frame: Every 6 months up to 24 months ]
    Changes in 5-HIAA levels between last 5-HIAA value prior to lanreotide start (if available) and values at each study visit

  9. Changes of pro-Brain Natriuretic Peptide (proBNP) levels [ Time Frame: Every 6 months up to 24 months ]
    Changes in proBNP levels between last proBNP value prior to lanreotide start (if available) and values at each study visit

  10. Patient satisfaction [ Time Frame: Baseline visit and 12 months ]
    To evaluate patient' satisfaction (TSQM-9 questionnaire) at inclusion visit. Treatment Satisfaction Questionnaire for Medication (TSQM) is an instrument to assess patients' satisfaction with medication, providing scores on four scales - side effects, effectiveness, convenience and global satisfaction. The effectiveness scored as: 1 (extremely dissatisfied) to 7 (extremely satisfied). For the convenience scored as 1(extremely difficult) to 7 (extremely easy).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Hospital patients
Criteria

Inclusion Criteria:

  • Subjects aged ≥ 18
  • Subjects diagnosed of functioning or non-functioning PanNET, G1/ G2 (Ki67≤10%) unresectable locally advanced tumour or metastatic disease, who have been treated with lanreotide 120mg every 28 days for at least 3 months and a maximum of 12 months
  • Subject not progressive at inclusion study visit according to investigator assessment, and using as a reference lanreotide initiation
  • Subject with Eastern Cooperative Oncology Group (ECOG) ≤2

Exclusion Criteria:

  • Subject who is participating in an interventional study
  • Pregnant or breast-feeding women
  • Subject who has received any previous therapy for PanNET (such as octreotide LAR, Molecular Targeted Therapy (MTT), Peptide receptor radionuclide therapy (PRRT), chemotherapy, etc.) except short-acting octreotide subcutaneous (SC) used for symptomatic control of functioning tumours

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03947762


Contacts
Layout table for location contacts
Contact: Ipsen Recruitment Enquiries clinical.trials@ipsen.com

Locations
Layout table for location information
Spain
Hospital General de Alicante Not yet recruiting
Alicante, Spain, 03010
Hospital Torrecardenas Active, not recruiting
Almería, Spain, 04009
Hospital Universitario de Badajoz Not yet recruiting
Badajoz, Spain, 06010
ICO Badalona Not yet recruiting
Badalona, Spain, 08916
Hospital de Cruces Not yet recruiting
Baracaldo, Spain, 48903
Hospital Universitario Vall Hebrón Not yet recruiting
Barcelona, Spain, 08035
Hospital Basurto Not yet recruiting
Bilbao, Spain, 48013
Hospital Universitario de Burgos Not yet recruiting
Burgos, Spain, 09006
Hospital Universitario Puerto Real Active, not recruiting
Cadiz, Spain, 11510
Hospital General Ciudad Real Not yet recruiting
Ciudad Real, Spain, 13005
Hospital San Pedro de Alcántara Not yet recruiting
Cáceres, Spain, 10003
Hospital Universitario Reina Sofia Active, not recruiting
Córdoba, Spain, 14004
Hospital Donostia Not yet recruiting
Donostia, Spain, 20014
Hospital Virgen de las Nieves Active, not recruiting
Granada, Spain, 18014
ICO Bellvitge Not yet recruiting
Hospitalet de Llobregat, Spain, 08908
Hospital Juan Ramón Jimenez Recruiting
Huelva, Spain, 21005
Hospital Can Misses Not yet recruiting
Ibiza, Spain, 07800
Hospital de Jerez Active, not recruiting
Jerez De La Frontera, Spain, 11407
Hospital Santa María Nai Not yet recruiting
Ourense, Spain, 32005
Hospital Universitario Central de Asturias Not yet recruiting
Oviedo, Spain, 33011
Hospital Son Espases Not yet recruiting
Palma De Mallorca, Spain, 07120
Hospital de Navarra Not yet recruiting
Pamplona, Spain, 31008
Hospital Sant Joan de Reus Active, not recruiting
Reus, Spain, 43204
Hospital Clínico de Salamanca Not yet recruiting
Salamanca, Spain, 37007
Hospital Marqués de Valdecillas Not yet recruiting
Santander, Spain, 39008
Hospital Conxo Recruiting
Santiago De Compostela, Spain, 15706
Hospital Virgen Macarena Active, not recruiting
Sevilla, Spain, 41009
Hs. Virgen del Rocio Active, not recruiting
Sevilla, Spain, 41013
Hospital Mutua Terrassa Not yet recruiting
Terrassa, Spain, 08221
Hospital Virgen de la Salud Toledo Not yet recruiting
Toledo, Spain, 45004
Hospital General de Valencia Active, not recruiting
Valencia, Spain, 46014
Hospital Universitario y Politécnico La Fe Not yet recruiting
Valencia, Spain, 46014
Hospital Álvaro Cunqueiro Not yet recruiting
Vigo, Spain, 36312
Hospital Lozano Blesa Not yet recruiting
Zaragoza, Spain, 50009
Hospital Miguel Servet Not yet recruiting
Zaragoza, Spain, 50009
Sponsors and Collaborators
Ipsen
Investigators
Layout table for investigator information
Study Director: Ipsen Medical Director Ipsen

Layout table for additonal information
Responsible Party: Ipsen
ClinicalTrials.gov Identifier: NCT03947762     History of Changes
Other Study ID Numbers: A-ES-52030-383
IPS-LAN-2018-01 ( Other Identifier: Spanish Drug Agency AEMPS )
First Posted: May 13, 2019    Key Record Dates
Last Update Posted: July 25, 2019
Last Verified: July 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Neuroendocrine Tumors
Adenoma, Islet Cell
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Nerve Tissue
Adenoma
Neoplasms, Glandular and Epithelial
Pancreatic Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Endocrine Gland Neoplasms
Digestive System Diseases
Pancreatic Diseases
Endocrine System Diseases
Lanreotide
Angiopeptin
Antineoplastic Agents